Gefitinib has been reported to be a radiosensitiser, which inhibits radiation-induced phosphorylation of EGFR and the downstream pathway and therefore enhances radiosensitivity in cholangiocarcinoma cells [1, 19]. This evidence concerns the gene EGFR and cholangiocarcinoma.